The effect of hormone therapy on bone mineral density and cardiovascular factors among Iranian female athletes with amenorrhea/oligomenorrhea: A randomized clinical trial.

Functional hypothalamic menstrual disorder (FHMD) has a destructive effect on the athlete's bone mineral density and cardiovascular system. Utilizing hormone replacement therapy to treat FHMD in athletes is controversial. This study was conducted to examine the effect of hormone therapy on bone density and the cardiovascular system of professional female athletes with FHMD.

Bone Mineral Changes and Cardiovascular Effects among Female Athletes with Chronic Menstrual Dysfunction.

Purpose: Oligo/amenorrhea, as a part of the Female Athlete Triad has adverse effects on the athlete's bone mineral density (BMD) and cardiovascular system. Hypoestrogenism, due to suppression of hypothalamus-pituitary axis (HPA) as a result of energy imbalance, is the possible cause of the Triad. This study was designed based on following up and reassessment of elite female athletes who were diagnosed as menstrual dysfunction about two years ago.

Clinical manifestations of the female athlete triad among some Iranian athletes.

Purpose: The study's purpose was to evaluate clinical manifestations of the female athlete triad among some elite Iranian athletes.

Methods: This cross-sectional study was conducted in three phases: 1) screening for menstrual irregularity (oligomenorrhea/amenorrhea) and/or stress fracture and weight-reducing drugs, 2) measurement of bone mineral density by dual-energy x-ray absorptiometry, and 3) a clinical interview to diagnose eating disorders. Phases 2 and 3 were conducted in athletes who reported menstrual irregularity and/or stress fracture and weight-reducing drugs.